Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral medication
|
| gptkbp:approves |
gptkb:2020
gptkb:FDA |
| gptkbp:atccode |
L01 XE30
|
| gptkbp:casnumber |
606143-52-6
|
| gptkbp:chemical_formula |
C16 H14 F3 N3 O3 S
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase III
NCT01362803 NCT02096268 NCT02335918 NCT02989857 |
| gptkbp:clinical_use |
treatment of inoperable plexiform neurofibromas
|
| gptkbp:contraindication |
hypersensitivity to the drug
severe liver impairment |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:effective_date |
FDA approved
EMA approved |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Selumetinib
|
| gptkbp:indication |
gptkb:neurofibromatosis_type_1
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:lifespan |
approximately 8 hours
|
| gptkbp:marketed_as |
the brand name Koselugo
|
| gptkbp:mechanism_of_action |
MEK inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:patient_population |
pediatric patients
adult patients |
| gptkbp:pharmacokinetics |
absorbed in gastrointestinal tract
inhibits MEK1 and MEK2 |
| gptkbp:project |
clinical development
|
| gptkbp:research |
ongoing studies for other cancers
studies on dosing regimens investigating combination therapies studies on long-term effects studies on efficacy in adults studies on efficacy in children |
| gptkbp:research_areas |
oncology
rare diseases |
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:targets |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:treatment |
with other cancer drugs
|
| gptkbp:used_for |
gptkb:cancer_treatment
|
| gptkbp:bfsParent |
gptkb:Astra_Zeneca
|
| gptkbp:bfsLayer |
4
|